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OBJECTIVE—Relatives of type 1 diabetic patients are at en-
hanced risk of developing diabetes. We investigated the mode of
onset of hyperglycemia and how insulin sensitivity and -cell
function contribute to the progression to the disease.
RESEARCH DESIGN AND METHODS—In 328 islet cell
autoantibody–positive, nondiabetic relatives from the obser-
vational arms of the Diabetes Prevention Trial-1 Study (me-
dian age 11 years [interquartile range 8], sequential OGTTs
(2,143 in total) were performed at baseline, every 6 months,
and 2.7 years [2.7] later, when 115 subjects became diabetic.
-Cell glucose sensitivity (slope of the insulin-secretion/
plasma glucose dose-response function) and insulin sensitivity
were obtained by mathematical modeling of the OGTT glucose/
C-peptide responses.
RESULTS—In progressors, baseline insulin sensitivity, fasting
insulin secretion, and total postglucose insulin output were
similar to those of nonprogressors, whereas -cell glucose sen-
sitivity was impaired (median 48 pmol/min per m
2 per mmol/l
[interquartile range 36] vs. 87 pmol/min per m
2 per mmol/l [67];
P  0.0001) and predicted incident diabetes (P  0.0001)
independently of sex, age, BMI, and clinical risk. In progressors,
2-h glucose levels changed little until 0.78 years before diagnosis,
when they started to rise rapidly (13 mmol  l
1  year
1);
glucose sensitivity began to decline signiﬁcantly (P  0.0001)
earlier (1.45 years before diagnosis) than the plasma glucose
surge. During this anticipation phase, both insulin secretion and
insulin sensitivity were essentially stable.
CONCLUSIONS—In high-risk relatives, -cell glucose sensitiv-
ity is impaired and is a strong predictor of diabetes progression.
The time trajectories of plasma glucose are frequently biphasic,
with a slow linear increase followed by a rapid surge, and are
anticipated by a further deterioration of -cell glucose
sensitivity. Diabetes 59:679–685, 2010
T
he onset of type 1 diabetes typically is acute. The
immune-mediated destruction of pancreatic
-cells, however, is known to occur over years
(1,2). During this prodromic phase, several
classes of autoantibodies can be detected in the serum of
many, though not all, subjects progressing to diabetes
(3–5). Number and titer of such autoantibodies mark the
risk of disease, particularly in genetically predisposed
individuals (6), but do not tell when hyperglycemia will
emerge (7). What precipitates -cell failure remains un-
known. A reduced acute insulin response to an intrave-
nous glucose challenge is thought to reﬂect reduction of
-cells below a critical mass or function and is used as a
metabolic marker of future diabetes (8,9), but the natural
history of -cell incompetence has not clearly been de-
ﬁned. Furthermore, the contribution of insulin resistance
to metabolic decompensation is controversial. Thus, in the
Seattle Family Study, insulin sensitivity (as the SI from an
intravenous glucose challenge) did not distinguish be-
tween progressors and nonprogressors (10); likewise, in-
sulin resistance (as the homeostasis model assessment of
insulin resistance index) did not affect progression when
insulin secretion was relatively well preserved in the
ENDIT study (11). In contrast, in the Melbourne Pre-
diabetes Family study, Fourlanos et al. (12) found that
insulin resistance (as the homeostasis model assessment
of insulin resistance factored by acute insulin response)
was a signiﬁcant predictor of incident type 1 diabetes over
a 4-year follow up. In any event, the interactions between
insulin release, -cell dysfunction, and insulin resistance
have not been dissected out.
The Diabetes Prevention Trial–Type 1 (DPT-1) recruited
a large number of autoantibody-positive relatives of pro-
bands with type 1 diabetes who were at risk of disease
because of multiple autoantibody positivity or reduced
acute insulin response to intravenous glucose (13). Oral
glucose tolerance was tested at frequent intervals over the
course of several years until appearance of diabetes or
study end (14). Measurement of the C-peptide response to
oral glucose makes it possible to quantify -cell function
and estimate insulin sensitivity (15). The DPT-1 cohort
was therefore uniquely suited to investigate mechanisms
and mode of onset of type 1 diabetes.
RESEARCH DESIGN AND METHODS
The DPT-1 screened 103,391 relatives of individuals with type 1 diabetes who
had been diagnosed before age 45 years. To have been eligible for screening,
an individual must have been a ﬁrst-degree relative of a patient with type 1
diabetes aged between 3 and 45 years or a second-degree relative aged
between 3 and 20 years. The 3,483 relatives who were found to be islet cell
–antibody (ICA) positive were staged to quantify the projected 5-year risk of
diabetes (13). Staging consisted of ICA conﬁrmation, HLA-DQ typing, deter-
mination of insulin autoantibodies, and oral (OGTT) and intravenous glucose
tolerance testing. Relatives with HLA-DQA 1*0102/DQB1*0602 were excluded
(16). Those considered to be at a 50% 5-year risk were eligible for entry into
the parenteral insulin trial if either the ﬁrst-phase insulin response to
intravenous glucose was below the 1st–10th percentile (depending on age and
relation to the proband) on two occasions or there were abnormalities (other
than diabetes) on the OGTT (17). If none of these metabolic abnormalities
were present, ﬁrst-phase insulin response was above threshold (10th
percentile for siblings, offspring, and second-degree relatives and 1st
percentile for parents), insulin autoantibodies were positive, and the 5-year
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diabetes.diabetesjournals.org DIABETES, VOL. 59, MARCH 2010 679risk was 25–50%, participants were entered for the oral insulin trial (18).
Subjects were randomly assigned to receive insulin intervention or matched
placebo/observation, respectively. Neither intervention showed a statistically
signiﬁcant difference between the treatment arms in terms of progression to
diabetes (17,18). We report here on the 180 participants in the oral insulin trial
(moderate-risk group) and the 148 subjects in the parenteral trial (high-risk
group) who were randomized to the placebo/observation arms of the study.
Study protocol. At baseline and follow up, the OGTT was performed using a
dose of glucose of 1.75 g/kg body wt (maximum 75 g). After an overnight fast,
blood samples were obtained through indwelling catheters for plasma glucose
and serum C-peptide measurements in the fasting state and 30, 60, 90, and 120
min later.
Follow-up. After the baseline study, subjects received an OGTT every 6
months until development of diabetes (median 2.2 years) or study end
(median 3.2 years). A total of 2,143 OGTTs were available for analysis.
Diagnosis of diabetes. Diabetes was diagnosed if the fasting glucose was
7.0 mmol/l or the 2-h glucose was 11.1 mmol/l, with conﬁrmation by either
an elevated fasting or 2-h glucose level at a special follow-up visit or a random
plasma glucose 11.1 mmol/l accompanied by symptoms of polyuria, poly-
dipsia, or weight loss. Impaired glucose tolerance (IGT) was deﬁned as a
fasting glucose 7.0 mmol/l and a 2-h glucose between 7.8 and 11.1 mmol/l
(19).
Analytical measurements. Plasma glucose was measured by the glucose
oxidase method. Serum C-peptide was determined by radioimmunoassay as
previously described (20), with an interassay coefﬁcient of variation of 6.9% in
a reference pool with relatively high values and 7.8% in a reference pool with
relatively low values.
Data analysis. Modeling methods are described in detail in an online
appendix, available at http://diabetes.diabetesjournals.org/cgi/content/full/
db09-1378/DC1. In brief, -cell function parameters were obtained from the
OGTT using a model (21) that describes the relationship between insulin
secretion and glucose concentration. Characteristic -cell function parame-
ters reported here are fasting insulin secretion rate (in picomoles per min per
square meter of body surface area); insulin output, i.e., the integral of insulin
secretion during the 2-h OGTT; and -cell glucose sensitivity, i.e., the mean
slope of the dose response relating insulin secretion to glucose concentration
within the observed glucose range. As deﬁned and used here, in vivo -cell
glucose sensitivity quantiﬁes an overall relationship and does reﬂect speciﬁ-
cally the cellular processes governing glucose sensing (glucose transport
through GLUT2, phosphorylation by glucokinase, etc.). Insulin sensitivity was
calculated using the oral glucose–derived insulin sensitivity index (OGIS)
(22), which provides a validated estimate of the glucose clearance (in
milliliters per min per square meter of body surface area) during the
insulin-stimulated conditions of the euglycemic-hyperglycemic clamp. The
time trajectories of glucose concentration and the model-derived parameters
were analyzed using a function of time capable of representing a biphasic
pattern, with an initial phase in which the variable changes slowly with time
and a late phase in which the change is accelerated.
Statistical analysis. All data are presented as median [interquartile range].
Group comparisons were performed using the Mann-Whitney U or Wilcoxon
signed-rank test (for unpaired and paired observations, respectively) and the

2 test for categorical variables. Kaplan-Meier plots were used to compare
diabetes-free survival curves by means of the log-rank 
2 statistic. Cox
proportional hazards models were used to estimate hazard ratios (HRs) (95%
CI). The proportional hazards assumption was conﬁrmed by examining the log
cumulative survival plots. P values are two sided, and P  0.05 was accepted
as statistically signiﬁcant. All analyses were performed using JMP, version 3.1
(SAS Institute, Cary, NC).
RESULTS
Baseline. Subjects who progressed to diabetes (progres-
sors) were younger and leaner than those who remained
diabetes free over the follow-up period and were more
often IGT than nonprogressors, as manifested by their
higher 2-h plasma glucose levels (Table 1). The insulin
secretion/plasma glucose dose-response curve was consid-
erably ﬂatter in progressors than in nonprogressors. Its
descriptive parameter, the slope or -cell glucose sensitiv-
ity, was 45% lower in progressors, whereas fasting insulin
secretion rate, total insulin output, and insulin sensitivity
were similar in the two groups. After excluding subjects
with IGT (30 progressors and 18 nonprogressors), glucose
sensitivity was still signiﬁcantly impaired in subjects con-
verting to diabetes (median 54 pmol/min per m
2 per
mmol/l [interquartile range 38] vs. 90 pmol/min per m
2 per
mmol/l [73] of nonprogressors; P  0.0001) (Fig. 1).
In female subjects, younger age and higher BMI were
positive predictors of incident diabetes, whereas a good
TABLE 1
Anthropometric and metabolic parameters at baseline
Nonprogressors Progressors P*
n 213 115
Sex (male/female) 118/95 57/58 ns
Age (years) 11.7 (8.8) 9.7 (5.4) 0.0006
Height (m) 1.49 (0.41) 1.41 (0.32) 0.015
Weight (kg) 41 (38) 35 (26) 0.02
BMI (kg/m
2) 18.7 (6.6) 18.0 (5.7) ns
Fasting glucose (mmol/l) 4.77 (0.55) 4.83 (0.74) ns
2-h glucose (mmol/l) 5.94 (1.78) 6.83 (1.88) 0.0001
NGT/IGT (%) 92/8 74/26 0.0001
Fasting insulin secretion (pmol/min per m
2) 52 (36) 48 (36) ns
Insulin output (nmol/m
2) 28 (15) 26 (13) ns
Glucose sensitivity (pmol/min per m
2 per mmol/l) 87 (67) 48 (36) 0.0001
Insulin sensitivity (ml/min per m
2) 434 (76) 432 (76) ns
Data are median (interquartile range) or n unless otherwise indicated. *Progressors vs. nonprogressors. ns, not signiﬁcant.
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FIG. 1. Dose-response curve of insulin secretion rates vs. plasma
glucose levels during the OGTT in 280 subjects with normal glucose
tolerance according to whether (progressors) or not (nonprogressors)
they developed diabetes. Data are means  SEM. The mean slope of the
dose response is -cell glucose sensitivity. Full lines, baseline data;
dotted lines, data at follow-up.
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male subjects, only a younger age was a risk factor, while
both -cell glucose sensitivity and insulin sensitivity were
protective (Table 2). Of note is that a high a priori risk
(assessed at staging as a composite of relation to proband
and reduced acute insulin response to intravenous glu-
cose) was a signiﬁcant predictor of conversion to diabetes
only in female subjects and did not replace either glucose
sensitivity or insulin sensitivity. With regard to plasma
glucose levels themselves, in univariate analysis 2-h glu-
cose levels predicted incident diabetes, with HRs (1.81
[95% CI 1.37–2.40], 
2  16 in male subjects and 2.35
[1.72–3.21], 
2  29 in female subjects) that were lower
than the univariate HRs carried by -cell glucose sensitiv-
ity (0.32 [0.17–0.56], 
2  20 in male subjects and 0.24
[0.14–0.38], 
2  46 in female subjects). Thus, in the
multivariate models of Table 2, neither fasting nor 2-h
glucose was a signiﬁcant independent predictor in male
subjects and only 2-h glucose was an additional predictor
in female subjects (P  0.03). Even in subjects with
normal glucose tolerance (n  280), diabetes-free survival
was strongly dependent on baseline -cell glucose sensi-
tivity in both sexes (Fig. 2).
Follow-up. Fasting and 2-h plasma glucose concentra-
tions had risen slightly in nonprogressors, who now
counted as 41 subjects in the IGT category. Both fasting
insulin secretion rate and insulin output were higher than
at baseline, whereas insulin sensitivity and -cell glucose
sensitivity were slightly but signiﬁcantly worse. In progres-
sors, the marked rise in fasting and 2-h plasma glucose
levels was accompanied by a fall in insulin output and
insulin sensitivity and a further, drastic decline in glucose
sensitivity (Table 3).
Time trajectories. In the subjects with four or more
sequential OGTTs (n  208), the individual time series
could generally be described as approximately linear with
time (i.e., a monophasic time course) or as biphasic (i.e.,
displaying a deﬁnite change in slope at an identiﬁable
transition time) (Fig. 3). For the 2-h plasma glucose
concentrations, both the raw values and their ﬁtting func-
tions revealed a predominantly biphasic pattern in pro-
gressors (n  52) and a mostly monophasic one among
nonprogressors (n  156) (Fig. 4). The statistical analysis
of all the OGTT-derived parameters is given in supplemen-
tal Table A1. For 2-h glucose concentrations, glucose
sensitivity, and insulin sensitivity, the average time course
was signiﬁcantly better described by a biphasic than a
monophasic ﬁt in progressors compared with nonprogres-
sors. Accordingly, the initial and ﬁnal slopes of the respec-
tive time series were not different from one another in
nonprogressors, whereas the ﬁnal slopes were much
steeper than the initial slopes in the progressors. This
difference in time course was not found for fasting insulin
secretion rate.
Among progressors, 36 subjects (or 70%) had a biphasic
time course for 2-h glucose levels (on a median of 6
[interquartile range 2] tests), while for glucose sensitivity a
similar pattern was present in 30 subjects. In these indi-
viduals, the transition time for 2-h glucose was positively
correlated with the transition time for glucose sensitivity
(0.43; P  0.020). In addition, the transition to an
increased rate of decrease in glucose sensitivity occurred
earlier than the corresponding 2-h glucose transition (1.3
TABLE 2
Predictors of incident type 1 diabetes
Risk ratio (95% CI) P
Female subjects (n  153)
Risk at staging (high vs.
moderate) 1.75 (1.25–2.48) 0.001
Age 0.30 (0.17–0.50) 0.0001
BMI 2.25 (1.31–3.79) 0.003
-Cell glucose sensitivity 0.29 (0.17–0.47) 0.0001
Insulin sensitivity 0.76 (0.53–1.09) 0.133
Male subjects (n  175)
Risk at staging (high vs.
moderate) 1.12 (0.83–1.52) 0.465
Age 0.55 (0.35–0.81) 0.002
BMI 1.27 (0.72–2.13) 0.403
-Cell glucose sensitivity 0.29 (0.15–0.53) 0.0001
Insulin sensitivity 0.46 (0.29–0.73) 0.001
Multivariate analysis; risk ratios for age, BMI, -cell glucose sensi-
tivity, and insulin sensitivity were calculated for the sex-speciﬁc
interquartile range of their respective values.
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FIG. 2. Kaplan-Meier plots of diabetes-free survival in 280 subjects with normal glucose tolerance at baseline according to tertile of baseline
-cell glucose sensitivity (log-rank 
2  25.5, P < 0.0001, and 13.2, P  0.0003, in female [A] and male [B] subjects, respectively). The risk ratio
of subjects in the bottom tertile of -cell glucose sensitivity (dotted line) is 2.40 (95% CI 1.76–3.30), P < 0.0001 vs. the top tertile, adjusted for
sex, age, and BMI.
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glucose levels were synchronized on the individual transi-
tion times, it became clear that plasma glucose levels
changed little until 0.78 years before diagnosis, when they
started to rise at a rate of 13 mmol/l per year. When the
time series of the metabolic parameters were synchro-
nized with the glucose time series, it was found that
glucose sensitivity had begun to decline (at a rate of 29
pmol/min per m
2 per mmol/l) 1.45 years before diagnosis,
i.e., signiﬁcantly (P  0.0001) earlier than the plasma
glucose surge. During this anticipation phase–lasting a
median 4.3 months–both insulin secretion and insulin
sensitivity were essentially stable. In progressors (n  30)
with an unequivocally biphasic time course of 2-h glucose
concentrations, the transition times of -cell glucose sen-
sitivity were positively associated with the transition times
of 2-h plasma glucose concentration (supplemental
Fig. A1).
DISCUSSION
By selection, our subjects were at enhanced risk of
progressing to diabetes by genetic makeup (kinship and
lack of protective genotype) as well as clinical phenotype
(presence of ICA and insulin autoantibodies or reduced
acute insulin response to intravenous glucose). Accord-
ingly, 35% developed diabetes over the follow-up period, a
crude rate of 13% per year (in the range of that of similar
cohorts [23,24]). The most striking ﬁndings relate to -cell
function. At baseline, insulin secretion rates and insulin
sensitivity were no different between progressors and
nonprogressors while -cell glucose sensitivity was mark-
edly impaired (by 45%). This was true also when com-
paring only NGT subjects (Fig. 1), and was only reﬂected
in a 0.78 mmol/l difference in 2-h glucose concentrations
while fasting glucose was virtually identical (median 4.83
mmol/l [interquartile range 0.72] vs. 4.80 mmol/l [0.63]).
Over time, some deterioration of all metabolic parameters
was seen in the whole cohort; emergence of overt diabe-
tes, however, was marked by a further, drastic (70%)
decline in -cell glucose sensitivity (Table 2). Consistent
with these time-related changes are the predictive models
of incident diabetes: younger age and worse -cell glucose
sensitivity were the strongest independent predictors of
progression in both sexes, with BMI (in female subjects)
and insulin resistance (in male subjects) as additional risk
factors (Table 2).
These ﬁndings have pathophysiological implications.
First, absolute rates of insulin secretion (or plasma insulin
concentrations) do not track a failing -cell function. In
fact, fasting insulin secretion increased over time in pro-
TABLE 3
Anthropometric and metabolic parameters at follow-up
Nonprogressors (n  213) Progressors (n  115) P§
Follow-up (years) 3.2 (2.8) 2.2 (3.3) 0.0001
Age (years) 14.7 (9.6)* 12.0 (5.7)* 0.0001
Height (m) 1.63 (0.25)* 1.52 (0.30)* 0.0007
Weight (kg) 57 (33)* 47 (31)* 0.0035
BMI (kg/m
2) 21.1 (6.0)* 19.6 (6.1)* 0.05
Fasting glucose (mmol/l) 4.89 (0.65)* 5.75 (1.22)* 0.0001
2-h glucose (mmol/l) 6.27 (2.25)* 13.05 (6.52)* 0.0001
Glucose tolerance (NGT/IGT) (%) 81/19* — 0.0001
Fasting insulin secretion (pmol/min per m
2) 65 (33)* 65 (44)* ns
Insulin output (nmol/m
2) 31 (14)* 21 (15)* 0.0001
Glucose sensitivity (pmol/min per m
2 per mmol/l) 72 (57)* 17 (19)* 0.0001
Insulin sensitivity (ml/min per m
2) 411 (76)* 380 (77)* 0.0001
Data are median (interquartile range) or n unless otherwise indicated. §Progressors vs. nonprogressors. *P  0.01 vs. baseline. ns, not
signiﬁcant.
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FIG. 3. Example of a monophasic (A) (subject YW3599) and a biphasic (B) (subject HR2920) time course of 2-h plasma glucose concentrations;
note the change in slope at transition time in the biphasic time pattern.
MECHANISMS OF PROGRESSION TO TYPE 1 DIABETES
682 DIABETES, VOL. 59, MARCH 2010 diabetes.diabetesjournals.orggressors and nonprogressors alike, while even in progres-
sors insulin output was diminished by only 20% at the time
of diagnosis (Table 2). The time course of insulin secretion
rates in progressors (Fig. 5) is reminiscent of the invert-
ed-U shape of plasma insulin concentrations in individuals
progressing to type 2 diabetes (25), which is also termed
the Starling curve of the pancreas (26). On the other hand,
-cell glucose sensitivity was speciﬁcally associated with
glucose tolerance across groups and over time, was the
strongest predictor of the diabetes outcome, and declined
as a monotonical function of time in progressors (Fig. 5).
Thus, absolute insulin secretion rates can be viewed as
reﬂecting the secretory tone of the -cell, which adapts to
chronically raised glucose levels by upregulating release of
the hormone. Glucose sensitivity, in contrast, expresses
the ability of the -cell to quickly respond to acute changes
in plasma glucose levels in vivo, thereby directly control-
ling glucose tolerance. It is this latter function that we
found to be compromised long (years) before the onset of
type 1 diabetes. At this time, there was little in the clinical
and metabolic phenotype—other than a younger age (2
years) and a 15% increase in 2-h glucose concentrations—
that differentiated subjects who were to become diabetic
from those who remained nondiabetic over the observa-
tion period. Thus, in vivo -cell glucose insensitivity is an
early defect in type 1 diabetes.
The question stands whether the whole DPT-1 cohort—
and not just the subjects who progressed within 3
years—was one characterized by a defect in -cell glucose
sensitivity. The present study did not include a control
group matched to the DPT-1 participants. However, from
data collected in the RISC study (27) we selected 90 young
(median age 32 years [interquartile range 3]), lean (BMI
22.6 kg/m
2 [4.2]) volunteers with a negative family history
of diabetes in whom -cell function and insulin sensitivity
were assessed with the same methodology as used in the
present study. In these historical controls, median -cell
glucose sensitivity was 138 pmol/min per m
2 per mmol/l
(interquartile range 72) and insulin sensitivity was 460
ml/min per m
2 (69). Thus, this comparison suggests that
both -cell glucose sensitivity and insulin sensitivity may
have been less than normal even in the nonprogressors of
DPT-1 at the time of staging. Whether the DPT-1 popula-
tion had entirely normal metabolic functions prior to the
autoimmune attack on the -cell is not known.
Secondly, the tight association between -cell glucose
insensitivity and glucose tolerance does not per se estab-
lish a cause-effect link: a primary -cell defect can clearly
cause loss of glucose tolerance but might also result from
toxic effects of mild but persistent hyperglycemia on
-cells. It should be stressed that the primary -cell defect
could consist in a reduction in number of normally func-
tioning -cells, a dysfunction of a normal number of
-cells, or a combination of the two. In vivo assessment of
-cell glucose sensitivity does not allow for distinction
between these underlying defects. Glucose toxicity, on the
other hand, can acutely depress both the insulin secretory
response to glucose (28) and insulin sensitivity (29).
The time series analysis of our data shows that in
two-thirds of the progressors, the trajectory of plasma
glucose concentrations was distinctly biphasic, with a
slow rise turning into a brisk surge 0.7 years before
diagnosis (RESEARCH DESIGN AND METHODS). In these individu-
als, a transition of -cell glucose sensitivity from a ﬂat time
course to a clear decline occurred 1.4 years prior to
diagnosis and consistently anticipated the transition of
glucose levels (Fig. 5). In other words, the trajectories of
plasma glucose and -cell function were shifted with
respect to one another by 6–8 months, during which time
neither absolute insulin secretion nor insulin sensitivity
was changing appreciably. These ﬁndings provide strong
support for the conclusion that a loss of -cell glucose
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FIG. 4. Half-yearly averages of 2-h plasma glucose concentrations (left panel) and individual ﬁts of their time series (right panel)i n
nonprogressors and progressors. The thick lines are the mean of the individual ﬁtting functions.
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of hyperglycemia in high-risk subjects rapidly progressing
to diabetes. Of note is that recent work carried out in
nondiabetic patients undergoing pancreatectomy (30) has
revealed a curvilinear reciprocal association between 2-h
plasma glucose concentration and -cell relative volume,
suggesting that -cell function/mass may decrease initially
without much impact on glucose levels but then—beyond
a certain critical level—cause an exponential rise in
glycemia.
Finally, the characteristic biphasic time pattern of con-
version in DPT-1 screenees is consistent with a previous
preliminary ﬁnding from DPT-1 (15) and is reminiscent of
what happens in type 2 diabetes. In three prospective
analyses of incident type 2 diabetes (31–33), an accelera-
tion of plasma glucose increments preceded the emer-
gence of clinical diabetes by 3–6 years. The similarity is
striking: a few years (type 2 diabetes [31–33]) or months
(type 1 diabetes [present study]) before diagnosis, glucose
tolerance characteristically begins to deteriorate at a
much faster rate than during the preceding years. The fact
that the pathogenesis and natural history of the two forms
of diabetes are distinct suggests that a more general factor
may be at play. Glucose homeostasis relies on multiple
controls: to name only the main ones, insulin sensitivity of
liver, fat, and skeletal muscle tissues as well as -cell and
	-cell function. In the individual who is destined to be-
come diabetic—whether type 2 or type 1 diabetes—
several of the factors that govern glucose tolerance are
more or less altered, generating a critical state of instabil-
ity. In such a condition, phase transition can be triggered
by small further changes in the controlling variables and
occurs relatively rapidly. For type 1 diabetes (34), this
instability paradigm—borrowed from physics (35)—has
been formulated mathematically by rate equations describ-
ing the changes in numbers of -cells, macrophages, and
Th-lymphocytes eventually leading to self-sustained -cell
elimination. The conclusion of this theoretical study was
that onset of type 1 diabetes is due to a collective,
dynamical instability rather than being caused by a single
etiological factor (34). Our results support this paradigm.
In progressors, transition to the phase of rapid plasma
glucose increases was characterized by a precipitous fall
in insulin sensitivity plus an acceleration of glucose insen-
sitivity; in the meantime, insulin secretion was failing to
keep up with the rising glucose (Fig. 5). Thus, a state of
critical instability transitioned to a phase of impending
global failure. Different time patterns, linear or erratic,
could be equally explained by different combinations of
rates of failure of the determinants of glucose tolerance. In
summary, a defect in -cell glucose sensitivity is detect-
able in at-risk subjects years before diagnosis, anticipates
plasma glucose increments, and in combination with pro-
gressive insulin resistance and secretory insufﬁciency pro-
duces the acute hyperglycemia of type 1 diabetes.
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